Multiple Sclerosis MS is a chronic, often disabling disease that randomly attacks the central nervous system brain and spinal cord. The progress, severity and specific symptoms of the disease can not be predicted; symptoms may range from tingling and numbness to paralysis and blindness. MS is a devastating disease because people live with its unpredictable physical and emotional effects for the rest of their lives. MS is a well-known disease, but poorly understood.
Abstract Objectives To estimate the incidence and prevalence of multiple sclerosis MS by age and describe secular trends and geographic variations within the UK over the year period between and and hence to provide updated information on the impact of MS throughout the UK.
Design A descriptive study.
Main outcome measures Incidence and prevalence of MS per population. Secular and geographical trends in incidence and prevalence of MS. There was a consistent downward trend in incidence of MS reaching Peak incidence occurred between ages 40 and 50 years and maximum prevalence between ages 55 and 60 years.
Scotland had the highest incidence and prevalence rates in the UK. There is an increasing population living longer with MS, which has important implications for resource allocation for MS in the UK. Multiple Sclerosis, Epidemiology Background Individuals with multiple sclerosis MS can experience high levels of disability and impaired quality of life for prolonged periods.
The costs of the disease in the UK, including health and social care and productivity losses, are high and correlate with disease severity. National studies have been carried out in the past, but recent data are lacking.
No further ethical approval is required for studies using GPRD that do not involve patient contact. Hypothesis This was a descriptive study. Its aim was to estimate the incidence and prevalence of MS by age in men and women and to describe secular trends and geographic variations within the UK between and Study population The study population included all patients with acceptable data who contributed follow-up time to the database after GPRD defines a patient's data as unacceptable if there is evidence of poor data recording, non-contiguous follow-up or if their registration with the practice is temporary.
The first 2 years of follow-up time for each patient were treated as a screening period, and incidence and prevalence rates were calculated for follow-up time after the screening period. We chose this screening period because preliminary analyses showed that incidence rates were high in the first 2 years of follow-up and prevalence rates were low, particularly in the first year.
This is probably due to inclusion of patients with prevalent disease whose initial diagnosis pre-dated the computerisation of their practice's records.
The follow-up period ended with the earlier of either their transfer-out date or their practice's last data collection date. Incident cases were defined as the first occurrence of a code for MS if it occurred after the 2-year screening period.The Multiple Sclerosis Research Institute is a non-profit foundation started by Dr.
Jeffrey Greenstein to FIND, STOP, and CURE MS. Essay Multiple Sclerosis Jason Garoutte November 18, English / Mr. Blunt Multiple sclerosis is one of the most misunderstood diseases of this century.
Since it's discovery, there is still no known causes, no proven treatments, and no known cure, yet it affects possibly five hundred thousand people in . Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
MS lesions show a typical distribution pattern and primarily affect the white matter (WM) in the periventricular zone and in the centrum semiovale. To estimate the incidence and prevalence of multiple sclerosis (MS) by age and describe secular trends and geographic variations within the UK over the year period between and and hence to provide updated information on the impact of MS throughout the UK.
This was a population-based. Essay Multiple Sclerosis Jason Garoutte November 18, English / Mr. Blunt Multiple sclerosis is one of the most misunderstood diseases of this century. Since it's discovery, there is still no known causes, no proven treatments, and no known cure, yet it affects possibly five hundred thousand people in .
Current basic research in MS continues to clarify the complex pathobiology of the disease, with the goal of improved diagnosis, treatment, and prevention.